4-(2-(N-(-2-CARBOXAMIDOINDOLE)AMINIETHYL)- BENZENSULFONAMIDE ODER SULFONYLHARNSTOFFE ALS PDGF ANTAGONISTE

4-(2-(N-(-2-CARBOXAMIDOINDOLE)AMINIETHYL)- BENZENSULFONAMIDE ODER SULFONYLHARNSTOFFE ALS PDGF ANTAGONISTE

Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal a non-peptide PDGF antagonist such as 4-(2-(N-(2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas. The methods are useful in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MOYNIHAN, KRISTEN, M, ORME, MARK, W, HART, CHARLES, E
Format: Patent
Sprache:ger
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal a non-peptide PDGF antagonist such as 4-(2-(N-(2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The non-peptide PDGF antagonists may optionally be administered coordinately with heparin, whereby the coordinately administered of non-peptide PDGF antagonist and heparin are combinatorially effective in inhibiting intimal hyperplasia.